Camargo

OCTOBER 14, 2020

Each month, Camargo’s “In the News” series highlights important changes and advancements in the regulatory and development space and explores how those changes could impact your program. The FDA has also recently launched the Software Pre-Certification Pilot Program to provide an efficient regulatory framework for developers of SaMD products.

Development 196

Development Insulin Drug Delivery Production 196

BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 95

Insulin Drug Delivery Development Drugs 95

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

pharmaphorum

JULY 27, 2021

Drug delivery specialist Aptar Group has agreed a deal to take a near two-thirds share in Voluntis, a French developer of digital therapeutics (DTx), with a view to taking full control of the company later this year. per share in the initial deal, which will give it a 64.6% stake in the company.

Drug Delivery 111

Drug Delivery Insulin Cosmetics Development 111

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

Roots Analysis

SEPTEMBER 18, 2023

Therefore, medical technology is rapidly evolving, enabling more advanced and patient-friendly methods of drug delivery. In the pursuit of creating patient-centric healthcare solutions, the medical industry has witnessed a groundbreaking advancement in drug delivery with the emergence of large volume wearable injectors.

Drug Delivery 52

Drug Delivery Drugs Compliance Marketing 52

pharmaphorum

MAY 21, 2021

In SURPASS-4 – the last of Lilly’s registration studies for the dual GLP-1/GIP agonist – tirzepatide met all its primary and secondary objectives, besting treatment with insulin glargine, a long-acting human insulin product that is a mainstay of diabetes treatment, in diabetics with increased cardiovascular risk. Arecor alliance.

Trials 52

Trials Insulin Sales Drug Delivery 52